Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Shares Shorted: Short Interest Down 61.8% in September

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) saw a large drop in short interest in the month of September. As of September 15th, there was short interest totaling 24,713 shares, a drop of 61.8% from the August 31st total of 64,641 shares. Currently, 0.5% of the company’s stock are short sold. Based on an average daily volume of 20,204 shares, the days-to-cover ratio is presently 1.2 days.

Analyst Upgrades and Downgrades

NEUP has been the topic of several recent research reports. Wall Street Zen raised Neuphoria Therapeutics to a “hold” rating in a research note on Saturday, July 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a report on Thursday, August 27th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $7.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AdvisorShares Investments LLC raised its stake in Neuphoria Therapeutics by 15.8% during the first quarter. AdvisorShares Investments LLC now owns 155,367 shares of the company’s stock valued at $632,000 after buying an additional 21,173 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in Neuphoria Therapeutics in the second quarter worth $131,000. Finally, Merck & Co. Inc. purchased a new stake in shares of Neuphoria Therapeutics in the second quarter worth $43,818. Institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Stock Performance

Shares of NASDAQ NEUP remained flat at $3.65 on Monday. 2,878 shares of the company’s stock were exchanged, compared to its average volume of 95,513. Neuphoria Therapeutics has a fifty-two week low of $3.19 and a fifty-two week high of $21.40. The company has a 50 day moving average of $3.78 and a 200 day moving average of $4.28. The stock has a market cap of $19.75 million, a P/E ratio of -0.59 and a beta of 0.75.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for obesity and other metabolic diseases. The company’s research programs are designed to address conditions involving weight management, diabetes and metabolic dysfunction.

Neuphoria’s pipeline includes DA-1726, an investigational dual GLP-1 and glucagon receptor agonist being developed for obesity and related metabolic conditions. The company is also developing DA-1241, an investigational GPR119 agonist intended for metabolic dysfunction-associated steatohepatitis, formerly known as nonalcoholic steatohepatitis, and other metabolic disorders.